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RESEARCH ARTICLE
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Early markers to predict delayed kidney graft function (DGF) may support clinical manage-
ment. We studied the ability of four biomarkers (neutrophil gelatinase associated lipocalin
(NGAL), liver-type fatty acid-binding protein (L-FABP), cystatin C, and YKL-40) to predict
DGF after deceased donor transplantation, and their association with early graft function
and GFR at three and twelve months.
Methods
225 deceased donor kidney transplant recipients were included. Biomarkers were mea-
sured using automated assays or ELISA. We calculated their ability to predict the need for
dialysis post-transplant and correlated with the estimated time to a 50% reduction in plasma
creatinine (tCr50), measured glomerular filtration rate (mGFR) and estimated GFR (eGFR).
Results
All biomarkers measured at Day 1, except urinary L-FABP, significantly correlated with
tCr50 and mGFR at Day 5. Plasma NGAL at Day 1 and a timed urine output predicted DGF
(AUC = 0.91 and AUC 0.98). Nil or only weak correlations were identified between early bio-
marker levels and mGFR or eGFR at three or twelve months.
Conclusion
High plasma NGAL at Day 1 predicts DGF and is associated with initial graft function, but
may not prove better than P-creatinine or a timed urine output. Early biomarker levels do not
correlate with one-year graft function.
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Delayed graft function (DGF) is a frequent complication after deceased donor kidney trans-
plantation. Incidence ranges from 28–38% in kidneys from brain dead donors (DBD)[1–3],
and up to 85% in kidneys from donors after circulatory death (DCD)[4–6]. DGF is related to
ischemia-reperfusion injury[7–9] and is associated with prolonged hospitalization in addition
to an increased risk of complications and acute rejection[7,10–12]. Moreover, in some studies
DGF is associated with reduced long-term graft function and graft survival[13].
DGF is most frequently defined as “the need for dialysis during the first week after trans-
plantation”. The time to a 50% reduction in plasma (P-) creatinine (tCr50) has been proposed
as an additional definition correlating with one year graft function [14]. Unfortunately, DGF
defined by these criteria cannot be assessed until several days after transplantation[15,16]. Fur-
thermore, changes in P-creatinine during the early post-transplant period do not always corre-
spond to changes in glomerular filtration rate (GFR), and may represent pre-renal and quickly
reversible changes, as well as kidney cellular damage[16,17]. Early prediction of DGF may help
to optimise clinical management immediately after transplantation and will allow early prepa-
ration for dialysis.
Several, renal biomarkers have been associated with ischemia-reperfusion injury in kidney
transplantation, but their ability to predict DGF has not been well established[16,18,19]. P-
neutrophil gelatinase associated lipocalin (NGAL) levels are elevated in patients with end stage
renal disease[20]. High concentrations of NGAL in serum and urine on the first post-trans-
plant day have been associated with risk of DGF[3,21–24]. Increased urinary (U) liver-type
fatty acid-binding protein (L-FABP) levels have been identified in renal transplant patients
with low graft function[25] and are associated with increased ischemia time, reduced peritubu-
lar capillary blood flow, and longer hospitalization in renal transplant recipients[26]. U-cysta-
tin C excretion predicted the need for renal replacement therapy in patients with acute tubular
necrosis[27]. Increased U-chitinase-3-like protein 1 (YKL-40) concentrations have been
observed in the first 24 hours post-transplant in patients with DGF when compared to patients
with slow or immediate graft function[28].
Our aim was to evaluate the levels and changes in 1) U- and P-NGAL, 2) U-L-FABP, 3) U-
cystatin C, and 4) U-YKL-40 following deceased donor kidney transplantation and to correlate
these biomarkers with DGF, early graft function, including measured GFR and estimated GFR
after one year. Furthermore, we compared these biomarkers to established clinical markers
such as post-transplant P-creatinine, urine output, and U-albumin/creatinine ratio.
Materials and methods
Study design
This study analyzed samples and outcome measurements from patients included in the CON-
TEXT trial (ClinicalTrials.gov: NCT01395719)[29]. This European multicenter randomized
controlled trial studied the effect of remote ischemic conditioning by repetitive inflation and
deflation of a cuff around the thigh of the recipient. The intervention was without any effect
on the primary endpoint of tCr50 or other markers of early graft function including DGF[29].
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The CONTEXT study was approved by the relevant national data protection agencies and ethi-
cal committees in the countries involved (Denmark: The National Committee on Health
Research Ethics; Sweden: Regional Ethical Board; the Netherlands: METCUMCG). Informed
and written consent was obtained prior to inclusion and the study was conducted in adherence
with the Declaration of Helsinki.
Inclusion
Patients undergoing deceased donor kidney transplantation were included from June 12,
2011, to December 28, 2014, at four transplant centres: Aarhus, Denmark; Gothenburg, Swe-
den; and Groningen and Rotterdam, the Netherlands[29].
Demographic data, P-creatinine levels and information on any dialysis procedures, were
collected from hospital records. Donor characteristics were obtained from ScandiaTransplant
(Aarhus and Gothenburg) and donor forms from Eurotransplant (the Netherlands). Kidney
graft function was estimated at three and twelve months (to January 31, 2016) using P-creati-
nine, mGFR, and eGFR.
Blood and urine sampling
Plasma and urine samples for biomarker evaluation were collected at four time points: after
induction of anesthesia and insertion of a urinary catheter prior to transplantation (baseline),
90 minutes after reperfusion of the kidney and Day 1 and Day 3 after transplantation (S1 Fig,
S1 Table). Samples were stored at room temperature for a maximum of one hour, centrifuged
at 2800G at 4˚C for ten minutes, and stored at -80˚C.
P-creatinine was measured once or twice daily during the first week after transplantation,
twice weekly until 30 days after transplantation, or in the case of dialysis after transplantation,
until 30 days after the last dialysis[29].
A 24hr urine sample was collected on Day 1 from patients included in Aarhus and Gothen-
burg (S1 Table). Urine output was calculated as the average milliliter output per hour during
the collection period.
Delayed graft function
DGF was defined as the need for dialysis within the first week after transplantation.
Biochemical analyses
NGAL was measured in plasma and urine at the Department of Clinical Biochemistry, Aarhus
University Hospital (AUH) using a particle-enhanced turbidimetric immunoassay (BioPorto
Diagnostics A/S, Hellerup, Denmark). U-cystatin C was measured at the Department of Clini-
cal Biochemistry at Viborg Regional Hospital using an automated particle-enhanced turbidi-
metric immunoassay (Gentian, Moss, Norway). U-YKL-40 was measured using a commercial
sandwich ELISA (Bio-Techne, Minneapolis, USA). The YKL-40 kit was validated for measure-
ments in urine before analysing the samples. The inter- and intra-assay coefficients of variance
(CV%) were estimated to�7.1% and�8.2% respectively. U-L-FABP was measured using
sandwich ELISA (CMIC HOLDINDS Co., Ltd., Tokyo, Japan) with an inter- and intraassay
CV% of�12.7% and�10.3%, respectively. All analyses were performed according to manu-
facturer’s instructions.
P-creatinine, U-creatinine, and U-albumin were measured at the local Department of Clini-
cal Biochemistry using automated, standard clinical assays.
A clinical trial on renal biomarkers in kidney transplantation
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All urinary biomarkers were normalized to U-creatinine level. tCr50 was calculated by
modelling the changes in P-creatinine for each patient as previously described[29].
Glomerular filtration rate
GFR was measured after transplantation in patients with definite evidence of kidney graft
function using 51Chrome-ethylenediamine tetraacetic acid (51Cr-EDTA) plasma clearance
[30]. The mGFR was standardized to body surface area.
eGFR was calculated for all patients using the Modification of Diet in Renal Disease
(MDRD) formula[31] without correction for race (>90% of included patients were Caucasian).
Statistical analyses
Donor and recipient characteristics are presented as n (%), mean (SD), or median (interquar-
tile range). Data, which were not normally distributed were transformed by logarithmic or
square root transformation. Continuous variables were correlated using simple regression,
while multiple linear regression was applied to adjust for confounders or predictors and to
combine different biomarkers Linearity and distribution of the residuals was tested. We com-
pared biomarker levels between two groups using Student’s t-test and evaluated the ability of
the biomarkers to predict DGF using ROC analysis. The optimal cut-off was defined as the
largest sum of sensitivity and specificity. Data analyses were performed using Stata version 13
software for Windows (StataCorp LP).
Results
Recipient and donor characteristics
A total of 225 recipients were included in the CONTEXT trial, hereof only three was with-
drawn from the study (Fig 1). 200 received a kidney from a DBD and 22 received a kidney
from a DCD donor. Donor and recipient characteristics are listed in Table 1. Eleven patients
(nine DBD kidney recipients and two DCD kidney recipients) were excluded from the analyses
of tCr50 due to either graft removal within the first week after transplantation (n = 2) or pri-
mary non-function (n = 9). 74 patients (33%) experienced DGF. Dialysis was initiated prior to
Day 3 blood sampling in 89% of patients (n = 65) experiencing DGF. There was no difference
between patients with DGF and patients without DGF with respect to donor age, donor’s last
P-creatinine, recipient age, gender, baseline P-creatinine, or U-albumin/creatinine-ratio.
Effect of remote ischemic conditioning
The intervention (remote ischemic conditioning vs. sham) had no effect on any of the bio-
markers at any time point (S2 Fig). Consequently, data was pooled independently from the
intervention.
Effect of variations in the time between reperfusion time and blood and
urine sampling
Since blood and urine samples on Day 1 were always collected during daytime working hours on
the day after surgery, the time between reperfusion and sampling on Day 1 varied. In order to
avoid any potential confounding as a result of this we used information from a subset of Aarhus
patients (n = 113 (plasma) and n = 89 (urine)) to analyse biomarker levels in blood and urine
depending on the time between reperfusion and sampling on Day 1. No correlation was observed
between the elapsed time to Day 1 blood sampling and P-NGAL neither in patients with DGF or
in patients without DGF suggesting that biomarker levels were not significantly depending on
A clinical trial on renal biomarkers in kidney transplantation
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differences in the time to first day sampling (S3 Fig). Similarly, no significant correlations were
observed between the elapsed time to Day 1 sampling and other biomarkers levels (U-NGAL:
p = 0.30, p = 0.13; U-cystatin C: p = 0.97, p = 0.23; U-L-FABP: p = 38, p = 0.71; U-YKL-40:
p = 0.60, p = 0.24. P-values are for patients with and without DGF respectively).
P-NGAL, P-creatinine and timed urine output predict DGF
The baseline P-NGAL was higher in patients experiencing DGF and remained elevated on
Day 1 and 3 while it decreased in patients that did not require dialysis (S4 Fig). Baseline
P-NGAL was approx. 1.8 times higher in patients on dialysis prior to transplantation when
compared to patients transplanted preemptive (p<0.001, Table 1). We also found that 40% of
Fig 1. Flowchart of inclusion and randomization.
https://doi.org/10.1371/journal.pone.0212676.g001
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the patients on dialysis prior to transplantation (n = 180) experienced DGF, whereas it was
only 5% of the preemptive patients (n = 40).
P-NGAL at Day 1 predicted DGF with a sensitivity of 84% and specificity of 87% (Table 2,
Fig 2) and an area under the ROC curve (AUC) of 0.91, and was superior to P-creatinine on
Day 1 (p = 0.02) and to the change in P-NGAL from baseline to Day 1 (p<0.001)(Table 2, Fig
2). Patients receiving dialysis prior to P-creatinine sampling on Day 1 were excluded from the
latter analysis.
In patients transplanted preemptive P-NGAL at Day 1 predicted DGF with AUC = 0.97
(n = 40) and in patients on dialysis prior to transplantation AUC = 0.90 (n = 162).
A timed urine sample was collected at Day 1 in 58% (n = 129) of the patients enrolled in
Aarhus and Gothenburg while nine patients were recorded as being anuric (urine output = 0),
allowing 138 patients (62%) for this analysis. In these patients, the urine output sampled at
Day 1 was superior to P-creatinine on Day 1 in prediction of DGF (AUC = 0.98 vs 0.80,
n = 138), but not to P-NGAL (AUC = 0.94, n = 122; p = 0.07). In 84 (38%) patients no infor-
mation on urine output was recorded on Day 1.
All urinary biomarkers measured on Day 1 were higher in patients with DGF compared to
those with primary function (S4 Fig). U-NGAL and U-albumin/creatinine ratios measured on
Day 1 predicted DGF (AUC’s of 0.82 and 0.84, Table 2). However, the biomarkers were
Table 1. Donor and recipient characteristics.
Donor and recipient characteristics
Donor age (years) (n = 222) 58 (51–65)
Donor female sex (n = 222) 101 (45%)
Donor’s last P-creatinine (μmol/l) (n = 190) 69 (54–88)
Cold ischemic time (h) (n = 219) 13.5 ±4.4
Recipient age (years) (n = 222) 59 (49–66)
Recipient female sex (n = 222) 88 (40%)
Recipient, preemptive transplantation (n = 222) 40 (18%)
Baseline P-creatinine (μmol/l) (n = 220) 636 (496–756)
Baseline P-NGAL (μg/l) (n = 218) 635 (453–848)
Baseline P-NGAL, preemptive (μg/l) (n = 40) 389 (332–485)
Baseline P-NGAL, on dialysis prior to TX (μg/l) (n = 178) 707 (512–889)
Baseline U-albumin/creatinine-ratio (mg/g) (n = 125) 688 (295–1905)
Baseline U-NGAL (ng/mg) (n = 122) 1784 (698–3924)
Baseline U-L-FABP (ng/mg) (n = 125) 112 (66–181)
Baseline U-cystatin C (mg/g) (n = 122) 15.4 (6.8–26.7)
Baseline U-YKL-40 (ng/mg) (n = 120) 54 (10–175)
Urine output Day 1a (ml/h) (n = 129) 92 (36–158)
Urine output Day 3a (ml/h) (n = 140) 92 (52–140)
Primary non-function (n = 222) 9 (4%)
mGFR Day 5 (ml/min/1.73m2) (n = 91) 33 (7–99)
tCr50 (days) (n = 211) 5.8 (1.8–10.9)
DGFb (n = 222) 74 (33%)
mGFR three months (ml/min/1.73m2) (n = 148) 43 (34–55)
mGFR twelve months (ml/min/1.73m2) (n = 141) 47 (35–60)
Values are mean ±SD, n (%) or median (interquartile range).
aOnly patients transplanted in Aarhus and Gothenburg.
bExcluding patients undergoing graftectomy within the first week after transplantation.
https://doi.org/10.1371/journal.pone.0212676.t001
A clinical trial on renal biomarkers in kidney transplantation
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inferior in predicting DGF when compared to P-creatinine, P-NGAL or the timed urine out-
put in patients where these were available (S5 Fig). In 13 (6%) patients urinary biomarkers
could not be measured due to anuria on Day 1.
Biomarker levels correlate with early graft function
P-NGAL on both Day 1 and Day 3 correlated with mGFR at Day 5 (r2adj. = 0.35, p<0.001 and
r2adj. = 0.56, p<0.001) and t50Cr (r
2
adj. = 0.31, p<0.001 and r
2
adj. = 0.52, p<0.001) (Table 3,
Fig 3). mGFR Day 5 was only measured in Aarhus and Gothenburg (n = 91). After adjustment
for age, sex, cold ischemic time, intervention, and urine output these correlations remained
significant. However, when further adjusted for the change in P-creatinine from baseline to
the time of sampling (Day 1 or 3) the correlation was only significant on Day 3 (Table 3). The
correlation coefficients for P-NGAL and P-creatinine with respect to mGFR Day 5 or tCr50
were similar for on both Day 1 and 3. In the subset of patients with a recorded urine output on
Day 1 this correlated moderately with mGFR Day 5 and tCr50 (Table 3).
U-NGAL, U-cystatin C, U-L-FABP and U-YKL-40 correlated to mGFR on Day 5 and
tCr50; however, all correlations were inferior to both P-NGAL and P-creatinine (S1 Table).
Similar calculations based on urinary biomarker concentration, without normalization to U-
creatinine, did not change the conclusions (S2 Table).
Combining the predictive information from each of the individual, urinary biomarkers
using multiple linear regression did not improve the correlations with mGFR on Day 5 or
tCr50 (S1 Table). The correlations between U-NGAL alone and mGFR on Day 5 or tCr50
were stronger than any combination of urinary biomarkers.
Cold ischemic time did not correlate with U-L-FABP
A prolonged cold ischemic time was associated with a lower mGFR on Day 5 and prolonged
tCr50 (p = 0.04 and p = 0.01, respectively). U-L-FABP correlated only weakly with cold ische-
mic time (S6 Fig).
Table 2. The ability of biomarkers to predict DGF. AUC = area under the ROC curve. Sens = sensitivity. Spec = specificity. aChange from baseline to Day 1. bPatients
receiving dialysis after transplantation but before sampling Day 1 were excluded.cOnly patients transplanted in Aarhus and Gothenburg.
Time of sampling
after reperfusion
n AUC ±SE Optimal cut-off
Cut-off Sens Spec
ΔP-NGALa - 176 0.76 ±0.04 -132 0.69 0.74
P-NGAL 90 minutes 208 0.69 ±0.04 614 0.67 0.71
P-NGAL Day 1 199 0.91 ±0.02 480 0.84 0.87
ΔP-creatininea,b - 194 0.89 ±0.02 29 0.92 0.78
P-creatinineb Day 1 195 0.82 ±0.04 647 0.69 0.86
Urine outputc Day 1 116 0.98 ±0.01 47 0.87 1.00
U-NGAL 90 minutes 136 0.67 ±0.06 1116 0.86 0.48
U-NGAL Day 1 171 0.82 ±0.04 829 0.79 0.76
U-L-FABP 90 minutes 135 0.52 ±0.07 559 0.33 0.80
U-L-FABP Day 1 173 0.76 ±0.05 156 0.64 0.87
U-Cystatin C
U-Cystatin C
90 minutes 135 0.63 ±0.06 13 0.70 0.49
Day 1 173 0.73 ±0.05 9 0.65 0.78
U-YKL-40
U-YKL-40
90 minutes 137 0.60 ±0.06 58 0.66 0.50
Day 1 173 0.78 ±0.04 46 0.85 0.61
U-albumin/creatinine
U-albumin/creatinine
90 minutes 137 0.62 ±0.06 2464 0.76 0.48
Day 1 174 0.84 ±0.04 1365 0.73 0.86
https://doi.org/10.1371/journal.pone.0212676.t002
A clinical trial on renal biomarkers in kidney transplantation
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Fig 2. Prediction of DGF. ROC-analyses (AUC) showing the ability to predict DGF for the timed urine output until Day 1 (n = 138), P-NGAL level on Day 1 (n = 199),
the change in P-creatinine levels from baseline to Day 1 (n = 194), and P-creatinine level on Day 1 (n = 195).
https://doi.org/10.1371/journal.pone.0212676.g002
Table 3. Correlations between P-NGAL, P-creatinine, or urine output and mGFR on Day 5 or tCr50.
Time of sampling mGFR Day 5 tCr50
Crude Adjusteda Adjustedb n p r2adj.
n p r2adj. n p r
2
adj. n p r
2
adj.
P-NGAL 90 minutes 89 0.45 0.00 60 0.99 0.26 - - -
P-NGAL Day 1 81 <0.001 0.35 53 0.01 0.35 53 0.55 0.41 192 <0.001 0.31
P-NGAL Day 3 86 <0.001 0.56 64 <0.001 0.61 64 <0.001 0.63 195 <0.001 0.52
P-creatininec Day 1 89 <0.001 0.30 60 0.001 0.39 60 0.12 0.45 189 <0.001 0.25
P-creatininec Day 3 84 <0.001 0.64 67 <0.001 0.66 67 <0.001 0.66 151 <0.001 0.52
Urine outputd Day 1 62 <0.001 0.24 60 <0.001 0.30 60 0.25 0.43 104 <0.001 0.24
Urine outputd Day 3 69 0.002 0.12 67 0.005 0.16 67 0.09 0.53 117 <0.001 0.13
aadjusted for recipient age, recipient sex, cold ischemic time, treatment, and urine output.
badjusted for a + change in P-creatinine from baseline to time of sampling (Day 1 or 3).
cExcluding patients receiving post-transplant dialysis.
dNot adjusted for urine output.
https://doi.org/10.1371/journal.pone.0212676.t003
A clinical trial on renal biomarkers in kidney transplantation
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Early biomarkers do not predict one-year graft function
Only very weak correlations were observed between the biomarkers on Day 1 and graft func-
tion at three or twelve months (Table 4). Early urine output did not correlate to any of the
one-year graft function parameters.
Discussion
This study has identified a strong correlation between P-NGAL measured on Day 1 and the
early kidney graft function. Furthermore, P-NGAL predicted DGF with acceptable sensitivity
and specificity. Urinary biomarkers, either individually or combined were only weakly corre-
lated to the initial graft function and DGF. In 62% of the patients, a 24hr urine output was
recorded on Day 1. In these patients, P-NGAL was not superior to the urine output in predict-
ing DGF, but the high number of missing samples limits the interpretation of this.
The finding that P-NGAL on Day 1 performed better when predicting DGF than P-creati-
nine on Day 1 is consistent with previous studies[3,20,32]. The AUC of ΔP-crea was similar to
the AUC of P-NGAL suggesting that the change in P-creatinine within the first day may be as
predictive as P-NGAL on Day 1. Interestingly, baseline P-NGAL prior to reperfusion was
Fig 3. The correlation between P-NGAL levels on Day 1 and 3 and early kidney graft function. A: Correlation between P-NGAL measured on Day 1 (dots)
or 3 (triangles) and mGFR at Day 5. B: Correlation between P-NGAL measured on Day 1 (dots) or 3 (triangles) and tCr50.
https://doi.org/10.1371/journal.pone.0212676.g003
Table 4. Correlations with graft function at three and twelve months. Simple linear regression showing the correlation between biomarkers or urine output measured
on Day 1 and kidney graft function (mGFR or eGFR) at three and twelve months.
Three months Twelve months
mGFR eGFR mGFR eGFR
n p r2adj. n p r
2
adj. n p r
2
adj. n p r
2
adj.
P-NGAL 135 0.05 0.02 188 0.07 0.01 128 0.02 0.04 180 0.07 0.01
U-NGAL 117 0.99 -0.01 163 0.62 0.00 114 0.22 0.00 156 0.13 0.01
U-L-FABP 119 0.81 -0.01 165 0.30 0.00 115 0.97 -0.01 158 0.46 0.00
U-cystatin C 119 0.27 0.00 165 0.24 0.00 116 0.04 0.03 158 0.06 0.02
U-YKL-40 119 0.22 0.00 165 0.02 0.03 115 0.02 0.04 158 0.03 0.02
Urine output 86 0.05 0.04 121 0.49 0.00 79 0.15 0.01 116 0.81 -0.01
https://doi.org/10.1371/journal.pone.0212676.t004
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elevated in patients who experienced DGF. This may indicate that recipient dependent factors
may affect both P-NGAL and an increased risk of DGF. Higher baseline levels were observed
in patients on dialysis prior to transplantation and these patients had as expected a higher risk
of experiencing DGF than patients transplanted preemptive. This may partly depend on the
residual function of the kidney. Unfortunately, data on residual function was not available in
this cohort. Nevertheless, P-NGAL on Day 1 also predicted DGF in this subgroup.
None of the biomarkers correlated well with graft function at three or twelve months post-
transplant. A review identified only one study showing that U-NGAL on Day 4 and Day 7 was
associated with serum creatinine twelve months after kidney transplantation whereas the
remaining, included studies found no association [22].
All urinary biomarkers, including U-albumin/creatinine ratio, correlated poorly with
mGFR on Day 5 and tCr50 when compared to P-NGAL or P-creatinine. Their ability to pre-
dict DGF was also poorer than P-NGAL, P-creatinine or urine output. Two previous studies
showed that U-NGAL on Day 2 predicted DGF better than P-creatinine, but no better than
urine output [24,33]. Both studies were smaller with 40 and 170 transplants patients respec-
tively. In contrast to these studies we measured the biomarkers in spot urine samples normal-
ized to U-creatinine levels[15]. This lead to different results as GFR and thus the urine
creatinine excretion rate is not in steady state immediately after kidney transplantation[34]. In
addition, the inter-individual variation in muscle mass and possible muscle injury associated
with surgery may also affect U-creatinine. Model calculations[34] and a previous study[2]
have suggested that normalization to U-creatinine may overestimate the biomarker excretion
rate; however, in our study the ability of these biomarkers to predict DGF was not improved
when recalculated using urinary biomarker concentration rather than the ratio to U-creati-
nine. In contrast to previous studies[1,35] the combination of several urinary biomarkers
using multiple regression analysis did not improve the correlation of urinary biomarkers with
mGFR on Day 5 or tCr50. Our findings thus suggest that even though the urinary biomarkers
may be pertinent in ischemia-reperfusion injury, their ability to predict early graft function
and DGF is poor in a clinical setting and in part be affected by missing data mainly due to
anuria.
The strength of this study is that a large, multicenter study on renal biomarkers in kidney
transplantation. Moreover, the patients in the study represent an unselected population of
deceased donor kidney transplant recipients. Our findings may be affected by the limitations
associated with normalizing urinary biomarkers as mentioned above. Measuring the bio-
marker excretion rate in a 24hr urine sample may prove more sensitive. However, this would
not only delay the measurements, but also be time consuming and possibly impractical in clin-
ical practice. In this study the collection of timed urine samples was in fact only possible in a
subset of the patients included in Aarhus and Gothenburg. Due to the clinical practice of rou-
tine blood and urine collection during daytime, the time between reperfusion and blood or
urine sampling on Day 1 varied. In principle, this may cause additional variation in Day 1 bio-
marker levels and reduce sensitivity and specificity. However, we did not identify any system-
atic difference between the time interval and biomarker levels neither in patients with or
patients without DGF indicating that this did not significantly affect the results. Furthermore,
the sampling procedure reflects the clinical practice in which biomarkers would have to be
applied.
In conclusion, P-NGAL measured on Day 1 post-transplant predicts DGF after deceased
donor kidney transplantation and correlates with early graft function, while the urinary bio-
markers U-NGAL, U-L-FABP, U-cystatin C, and U-YKL-40 correlated poorly and may not be
useful for predicting DGF. The urine output on Day 1 was more accurate than P-creatinine
and P-NGAL in predicting DGF; however, this is limited by the fact that a timed urine volume
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was only measured in 62% of the patients. None of the biomarkers measured on Day 1 were
useful for predicting graft function at three or twelve months.
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